JP6936815B2 - Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 - Google Patents
Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 Download PDFInfo
- Publication number
- JP6936815B2 JP6936815B2 JP2018562331A JP2018562331A JP6936815B2 JP 6936815 B2 JP6936815 B2 JP 6936815B2 JP 2018562331 A JP2018562331 A JP 2018562331A JP 2018562331 A JP2018562331 A JP 2018562331A JP 6936815 B2 JP6936815 B2 JP 6936815B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- het
- substituted
- cycloalkyl
- atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GPTUGFBGLQCERR-UHFFFAOYSA-O CC(C)[n](c(C(NC)=O)c1)nc1[N+](O)=O Chemical compound CC(C)[n](c(C(NC)=O)c1)nc1[N+](O)=O GPTUGFBGLQCERR-UHFFFAOYSA-O 0.000 description 1
- ZLOMRMTVSFENBP-UHFFFAOYSA-O CC(C)[n](c([N+](O)=O)c1)nc1C(NC)=O Chemical compound CC(C)[n](c([N+](O)=O)c1)nc1C(NC)=O ZLOMRMTVSFENBP-UHFFFAOYSA-O 0.000 description 1
- UPTIQMLLFYHQPD-UHFFFAOYSA-N CN(C1)C2C1CCNC2 Chemical compound CN(C1)C2C1CCNC2 UPTIQMLLFYHQPD-UHFFFAOYSA-N 0.000 description 1
- XKPWQAUVZANBIU-UHFFFAOYSA-N CN(C1)C2C1CNCC2 Chemical compound CN(C1)C2C1CNCC2 XKPWQAUVZANBIU-UHFFFAOYSA-N 0.000 description 1
- JEMUNAIYDRDREC-UHFFFAOYSA-N CN(C=C1[NH+]([O-])O)NC1=O Chemical compound CN(C=C1[NH+]([O-])O)NC1=O JEMUNAIYDRDREC-UHFFFAOYSA-N 0.000 description 1
- 0 CN(CC(*)(*)c1cc(-c2c(*)cnc([N-]*)n2)c2)c1c2C#N Chemical compound CN(CC(*)(*)c1cc(-c2c(*)cnc([N-]*)n2)c2)c1c2C#N 0.000 description 1
- OBAXRSXTJUNZRQ-UHFFFAOYSA-N CN1CC(C2)C2C1 Chemical compound CN1CC(C2)C2C1 OBAXRSXTJUNZRQ-UHFFFAOYSA-N 0.000 description 1
- YQURLNGUWNDBIR-UHFFFAOYSA-N CN1CC(CNC2)C2C1 Chemical compound CN1CC(CNC2)C2C1 YQURLNGUWNDBIR-UHFFFAOYSA-N 0.000 description 1
- YTKHEIJTGJUQFD-UHFFFAOYSA-O CO[N+](c1n[n](C2CCCC2)c(C(O)=O)c1)=O Chemical compound CO[N+](c1n[n](C2CCCC2)c(C(O)=O)c1)=O YTKHEIJTGJUQFD-UHFFFAOYSA-O 0.000 description 1
- RDZMEKBZANEQDL-UHFFFAOYSA-N C[NH+](c1cc(C(O)=O)n[n]1C1CCCC1)[O-] Chemical compound C[NH+](c1cc(C(O)=O)n[n]1C1CCCC1)[O-] RDZMEKBZANEQDL-UHFFFAOYSA-N 0.000 description 1
- YNTAYZIFUBFSNU-UHFFFAOYSA-N Cc1n[n](CC2CCN(CC(N(C)C)=O)CC2)c([N+]([O-])=O)c1 Chemical compound Cc1n[n](CC2CCN(CC(N(C)C)=O)CC2)c([N+]([O-])=O)c1 YNTAYZIFUBFSNU-UHFFFAOYSA-N 0.000 description 1
- KKGKHOSFZZIYEK-UHFFFAOYSA-O O=[NH+]c1c[nH]nc1OC1CC1 Chemical compound O=[NH+]c1c[nH]nc1OC1CC1 KKGKHOSFZZIYEK-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16177104.3 | 2016-06-30 | ||
| EP16177104 | 2016-06-30 | ||
| PCT/EP2017/066120 WO2018002217A1 (en) | 2016-06-30 | 2017-06-29 | Heteroaromatic derivatives as nik inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521097A JP2019521097A (ja) | 2019-07-25 |
| JP2019521097A5 JP2019521097A5 (cg-RX-API-DMAC7.html) | 2020-08-06 |
| JP6936815B2 true JP6936815B2 (ja) | 2021-09-22 |
Family
ID=56296645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562331A Active JP6936815B2 (ja) | 2016-06-30 | 2017-06-29 | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11136311B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3478675B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6936815B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102517352B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109641882B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017289315B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3027416A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2805976T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018002217A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6910359B2 (ja) | 2016-01-22 | 2021-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 |
| WO2017125534A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| JP6936815B2 (ja) | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
| AU2017289317B2 (en) | 2016-06-30 | 2021-04-01 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as NIK inhibitors |
| EP3801529B1 (en) | 2018-05-25 | 2023-10-11 | OncoCube Therapeutics LLC | Highly potent tacc3 inhibitor as a novel anticancer drug candidate |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| AU2019203034B1 (en) * | 2018-07-25 | 2019-09-26 | Hanmi Pharm. Co., Ltd. | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same |
| JP7577672B2 (ja) | 2019-02-22 | 2024-11-05 | ハンミ ファーマシューティカルズ カンパニー リミテッド | Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物 |
| FI3976597T3 (fi) | 2019-05-31 | 2024-09-25 | Janssen Pharmaceutica Nv | Nf-kb:tä indusoivan kinaasin pienimolekyylisiä estäjiä |
| KR102816656B1 (ko) * | 2019-06-25 | 2025-06-02 | 인벤티스바이오 컴퍼니 리미티드 | 헤테로고리 화합물, 이의 제조방법 및 이의 사용방법 |
| AU2020308814A1 (en) | 2019-06-27 | 2022-02-03 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents |
| CN117460724A (zh) * | 2021-04-12 | 2024-01-26 | A2A制药有限公司 | 用于治疗癌症的组合物和方法 |
| KR20250005157A (ko) | 2022-03-24 | 2025-01-09 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60039059D1 (de) * | 1999-10-07 | 2008-07-10 | Amgen Inc | Triazin-kinase-hemmer |
| MXPA02007957A (es) | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
| ES2254385T3 (es) | 2000-02-29 | 2006-06-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| ES2292753T4 (es) * | 2001-03-29 | 2009-02-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas. |
| JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ７に対するピリミジン阻害剤 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| US20110086834A1 (en) | 2008-06-26 | 2011-04-14 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| CA2986640C (en) | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| CN108752280A (zh) | 2009-08-17 | 2018-11-06 | 纪念斯隆-凯特琳癌症中心 | 热休克蛋白结合化合物、组合物以及其制备和使用方法 |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| ES2823350T3 (es) | 2010-07-29 | 2021-05-06 | Rigel Pharmaceuticals Inc | Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos |
| WO2012142329A1 (en) | 2011-04-12 | 2012-10-18 | Myrexis, Inc. | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors |
| TWI663166B (zh) | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
| WO2015030847A1 (en) | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| TWI704146B (zh) * | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物 |
| TWI627173B (zh) | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 |
| SG11201608242XA (en) | 2014-04-04 | 2016-10-28 | Syros Pharmaceuticals Inc | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2015176135A1 (en) | 2014-05-22 | 2015-11-26 | The University Of Sydney | Omega-3 analogues |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| WO2016049211A1 (en) * | 2014-09-26 | 2016-03-31 | Gilead Sciences, Inc. | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds |
| CN106928216A (zh) | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| JP6910359B2 (ja) | 2016-01-22 | 2021-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 |
| WO2017125534A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| SI3429591T1 (sl) | 2016-03-16 | 2023-07-31 | Kura Oncology, Inc. | Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe |
| AU2017289317B2 (en) | 2016-06-30 | 2021-04-01 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as NIK inhibitors |
| JP6936815B2 (ja) | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
-
2017
- 2017-06-29 JP JP2018562331A patent/JP6936815B2/ja active Active
- 2017-06-29 AU AU2017289315A patent/AU2017289315B2/en active Active
- 2017-06-29 ES ES17739902T patent/ES2805976T3/es active Active
- 2017-06-29 CN CN201780053583.6A patent/CN109641882B/zh active Active
- 2017-06-29 KR KR1020197002588A patent/KR102517352B1/ko active Active
- 2017-06-29 US US16/309,059 patent/US11136311B2/en active Active
- 2017-06-29 EP EP17739902.9A patent/EP3478675B1/en active Active
- 2017-06-29 WO PCT/EP2017/066120 patent/WO2018002217A1/en not_active Ceased
- 2017-06-29 CA CA3027416A patent/CA3027416A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3027416A1 (en) | 2018-01-04 |
| EP3478675A1 (en) | 2019-05-08 |
| KR20190025644A (ko) | 2019-03-11 |
| CN109641882B (zh) | 2022-10-28 |
| EP3478675B1 (en) | 2020-04-22 |
| US20190359598A1 (en) | 2019-11-28 |
| KR102517352B1 (ko) | 2023-03-31 |
| AU2017289315A1 (en) | 2019-01-24 |
| US11136311B2 (en) | 2021-10-05 |
| ES2805976T3 (es) | 2021-02-16 |
| AU2017289315B2 (en) | 2021-04-01 |
| JP2019521097A (ja) | 2019-07-25 |
| CN109641882A (zh) | 2019-04-16 |
| WO2018002217A1 (en) | 2018-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6936815B2 (ja) | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 | |
| KR102815634B1 (ko) | 면역조절제로서 복소환형 화합물 | |
| JP6910359B2 (ja) | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 | |
| JP6916796B2 (ja) | Ｎｉｋ阻害剤としての新たな６員のヘテロ芳香族置換シアノインドリン誘導体 | |
| JP6936814B2 (ja) | Ｎｉｋ阻害剤としてのシアノインドリン誘導体 | |
| JP6603713B2 (ja) | Ｎｉｋ阻害剤としての新規のチエノピリミジン誘導体 | |
| KR102662373B1 (ko) | Nik 억제제로서의 신규 치환 아자인돌린 유도체 | |
| RU2780577C2 (ru) | Новые замещенные производные азаиндолина в качестве ингибиторов nik | |
| HK1261385B (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| HK1261385A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190109 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20200601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200625 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200625 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20200625 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210415 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210701 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210810 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210827 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6936815 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |